Patents by Inventor Steven A. Fischkoff

Steven A. Fischkoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180264048
    Abstract: Provided herein are methods of using CD10+, CD34?, CD105+, CD200+ tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of diabetic peripheral neuropathy (DPN).
    Type: Application
    Filed: September 14, 2016
    Publication date: September 20, 2018
    Applicant: CELULARITY, INC.
    Inventors: Steven A. FISCHKOFF, Denesh CHITKARA
  • Publication number: 20170290861
    Abstract: Provided herein are methods of using tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of diabetic foot ulcer (DFU).
    Type: Application
    Filed: September 25, 2015
    Publication date: October 12, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Steven A. FISCHKOFF, Denesh CHITKARA, Uri HERZBERG, Vladimir JANKOVIC
  • Patent number: 9546212
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 17, 2017
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • Publication number: 20160280777
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Inventors: Steven A. FISCHKOFF, Joachim Kempeni, Roberta Weiss
  • Publication number: 20160030488
    Abstract: Provided herein are methods of using human placental stem cells in the treatment of subjects having acute kidney injury (AKI).
    Type: Application
    Filed: March 13, 2014
    Publication date: February 4, 2016
    Inventors: Steven A. Fischkoff, Hong-Jung Chen
  • Publication number: 20150368335
    Abstract: Methods of treating TNF?-related disorders comprising administering TNF? inhibitors, including TNF? antibodies are described.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 24, 2015
    Inventors: Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, Rebecca S. Hoffman, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff
  • Publication number: 20150246968
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 3, 2015
    Inventors: Steven A. FISCHKOFF, Joachim Kempeni, Roberta Weiss
  • Publication number: 20150218268
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Application
    Filed: April 8, 2015
    Publication date: August 6, 2015
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • Publication number: 20150218269
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Application
    Filed: April 8, 2015
    Publication date: August 6, 2015
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • Patent number: 9090689
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: July 28, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • Patent number: 9085620
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: July 21, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • Patent number: 9073987
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: July 7, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • Publication number: 20150175691
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Application
    Filed: February 27, 2015
    Publication date: June 25, 2015
    Inventors: Steven A. FISCHKOFF, Joachim Kempeni, Roberta Weiss
  • Publication number: 20150165023
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Application
    Filed: February 27, 2015
    Publication date: June 18, 2015
    Inventors: Steven A. FISCHKOFF, Joachim Kempeni, Roberta Weiss
  • Patent number: 9017680
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: April 28, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • Patent number: 8992926
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: March 31, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • Publication number: 20150079101
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 19, 2015
    Inventors: Steven A. FISCHKOFF, Joachim Kempeni, Roberta Weiss
  • Publication number: 20150071939
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Inventors: Steven A. FISCHKOFF, Joachim Kempeni, Roberta Weiss
  • Publication number: 20150071945
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 12, 2015
    Inventors: Steven A. FISCHKOFF, Joachim Kempeni, Roberta Weiss
  • Patent number: 8974790
    Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: March 10, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss